Boehringer Ingelheim focuses on the development of next generation NASH treatments that target all three key drivers of the disease - steatosis, inflammation and fibrosis
Collaboration aims to develop first-in-class dual agonist (GLP1R/FGF21R agonist) for NASH
Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties
INGELHEIM, Germany & SEOUL, South Korea -- (BUSINESS WIRE) --
Boehringer Ingelheim and Yuhan Corporation today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. The collaboration brings together Yuhan Corporation’s expertise in FGF21 biology, obesity and NASH with Boehringer Ingelheim’s pharmaceutical expertise and commitment to bringing innovative medicines to patients with cardiometabolic diseases.
NASH often starts with the accumulation of fat in the liver, giving rise to inflammation and finally leading in many patients to liver fibrosis and cirrhosis. It has an especially high prevalence among obese and diabetic patients and is an area of high-unmet medical need with no treatments currently available. Boehringer Ingelheim believes that in many cases approaches targeting one of the features of NASH will not be able to achieve the desired resolution of NASH in patients with advanced stages of the disease. Thus Boehringer Ingelheim has built a comprehensive program to develop next generation therapy approaches targeting all three key drivers of the disease - steatosis, inflammation and fibrosis.
Preclinical evidence suggests high efficacy, when combining the gut-derived hormone GLP-1 with FGF21. The dual agonist (GLP1R/FGF21R agonist) is expected to reduce liver cell injury and hepatic inflammation by resolution of steatohepatitis as well as having direct antifibrotic effects and complements Boehringer Ingelheim’s R&D portfolio in NASH adding another potential first-in-class opportunity.
“We are excited about this new opportunity which adds to our longstanding and successful partnership with Yuhan Corporation,” says Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the Innovation Unit. “This partnership brings us closer to next generation treatments for patients with NASH,” adds Pairet.
”We look forward to working jointly with Boehringer Ingelheim, with its strong track record of bringing new treatments to patients with cardiometabolic disease. Boehringer Ingelheim’s clinical expertise will now be applied to the development of this drug which has the potential to make a real difference for patients with NASH,” says Jung Hee Lee, CEO and President at Yuhan Corporation. “This molecule, which is a fusion protein utilizing the long-acting (HyFc) technology of Genexine, has been developed in-house by Yuhan Corporation. Not only is our collaboration with Boehringer Ingelheim on this molecule Yuhan’s first external partnership with biologics, it is also the very first out-licensing of biologics targeting NASH from Korea,” adds Mr. Lee.
Boehringer Ingelheim has a long history of excellence in the discovery and development of medicines for patients with cardiometabolic diseases. It has established a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute myocardial infarction, hypertension, and cardio-renal risk reduction. The cardiometabolic diseases pipeline extends beyond type 2 diabetes and anticoagulation with a focus on innovative drugs for the treatment of the devastating consequences of diabetes as well as contributing factors like obesity.
Yuhan Corporation has over many years been a commercial partner for selected Boehringer Ingelheim cardiovascular and metabolic products in Korea. Under the terms of the agreement Yuhan Corporation will receive an upfront and near term payments of USD 40 million and is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.
工商银行上饶分行多举措扎实开展金融知识宣传
Fujirebio与Agappe就CLIA免疫分析领域
武田发布AL淀粉样变3期试验TOURMALINE
上海佘山大仓酒店将于2024年开业
全球投资者法律顾问ROSEN提醒
Agthia推出首家在线椰枣拍卖平台eZad
交警抗洪突击队 全力保障抢险道路畅通
IDEMIA宣布RHB成为首家在东南亚推出
交管窗口服务延伸 零距离入户送到家
Aleph Farms 发布全新产品品牌
Visa的金融科技Fast Track计划走向全球并
百加得任命Tony Latham为执行副总裁兼首席财务官
玫琳凯与IMCAS学院合作继续通过教育资助支持科
莅临Milipol Paris(2019年11月19日
三部门将开展集中清查收缴非法枪爆物品统一行
广丰:开足马力 跨越赶超 实现工业经济强劲开
盈透证券集团欢迎Michael McClain加入公司
党史党建知识电视大赛圆满收官
全球投资者法律顾问ROSEN鼓励Icahn
上饶各地开展“世界食品安全日”宣传活动
MWC19上海展示全面交互的5G体验
芯原的AI处理器IP被用于下一代大屏幕智能家居
首尔半导体向2020款奥迪A4供应前大灯
CSG和Axiata Digital Labs加强与纳米比